United Therapeutics Grants & Scientific Sponsorships

Funding provided by United Therapeutics to an independent third party for scientific or medical educational activities (either accredited or non-accredited) that are non-promotional and developed by the third party without influence or control from United Therapeutics.

Funding is available for the following medical education objectives:

• Understand how the presence of pulmonary hypertension impacts outcomes of patients with interstitial lung disease.
• Improve screening and timely diagnosis of PH in ILD patients and increase awareness of treatment approaches.
• Recognize the importance of routine and formal risk assessment in PAH patients and the triggers and timing of therapy escalation, particularly in special populations (eg, CTD patients), as well as the need to achieve low risk status or hemodynamic remission.
• Understand the hemodynamics associated with PH and how different classes of therapies impact hemodynamic parameters.
• Improve patient selection and management of adverse events associated with various PAH therapies, particularly prostacyclin-class therapies, to increase persistence on therapy.
• Evaluate the clinical data associated with therapeutic transitions in PAH and how they apply to clinical practice.

Funding provided by United Therapeutics to national medical societies, national patient organizations, or similar major healthcare-related entities where only HCPs are in attendance.

In exchange, United Therapeutics receives direct tangible benefits such as corporate recognition, advertising, banners, signage, booth space and conference registration at a medical congress, society meeting, or similar event.